Introduction
The semaglutide patent has expired in India on March 20. Semaglutide is a GLP-1 receptor agonist widely used for managing type 2 diabetes and obesity. Semaglutide is sold with brand names like Ozempic and Wegovy by Novo Nordisk, a leading global healthcare company. With this key patent expired in Indian market, the country’s obesity and diabetes treatment landscape is about to shift.
Once a high-cost patented drug, semaglutide is now entering the generic space, with several Indian pharmaceutical companies launching their own versions.
It is fair to say that with rising obesity rates and growing demand for effective weight-loss treatments, this patent expiry is set to disrupt the Indian obesity drug market.
5 Ways the Semaglutide Patent Expiry Will Transform India’s Market
1. Affordable Obesity Treatment for the Mass Market
The most immediate impact of the semaglutide patent expiry is improved affordability. Generic semaglutide medicines are expected to be priced 50% to 80% lower than their branded counterparts. Currently, Ozempic is priced at approximately ₹8,800 to ₹11,175 per month in India, while Wegovy costs around ₹10,850 to ₹16,400 per month, depending on the dosage. As a result, the launch of generic alternatives is set to significantly enhance the affordability of weight-loss treatments in the Indian market.
As prices decline, access to these treatments is likely to expand among middle-income populations, driving adoption beyond metro cities and into Tier 2 and Tier 3 regions across India.
2. Surge in Generic Drug Manufacturers
India’s pharmaceutical sector is responding aggressively to the semaglutide patent expiry, with 10+ major companies already launching or preparing generic versions. Key players include Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Zydus Lifesciences, Natco Pharma, Glenmark Pharmaceuticals, Alkem Laboratories, and Torrent Pharmaceuticals.
Several branded generics have already entered the market. For example, Sun Pharma has launched Noveltreat and Sematrinity, Dr. Reddy’s Laboratories introduced Obeda, and Zydus launched Semaglyn, Mashema, and Alterme, while Glenmark introduced Glipiq.
The semaglutide patent expiry has triggered intense competition, with 50+ generic brands expected across injections, pens, and oral formats. This surge is strengthening supply chains and manufacturing capacity, while also unlocking B2B opportunities such as licensing deals (e.g., Natco partnering with Glenmark and Eris) and export expansion to global markets.
3. Rapid Growth of the Obesity Drug Market
The semaglutide patent expiry is expected to significantly accelerate market growth in India. Rising prevalence of obesity and diabetes, affecting over 77 million people with diabetes and with urban obesity rates exceeding 30%, is driving strong demand for effective therapies.
Increased awareness of medical weight-loss treatments, supported by global clinical adoption of GLP-1 drugs, is further boosting uptake. At the same time, expanding pharmacy networks and digital health platforms are improving accessibility. With the semaglutide patent shift, India’s market, projected to grow at a 17.8% CAGR through 2035, could become one of the fastest-growing obesity drug markets globally.
4. Regulatory Oversight and Safety Concerns
With the semaglutide patent expiry in India, significant regulatory challenges are also expected to emerge. As lower-cost alternatives enter the market, the risk of counterfeit and substandard drugs increases, posing concerns for patient safety and treatment efficacy.
This development highlights the growing responsibility of healthcare professionals to prescribe semaglutide only after verifying product quality and to guide patients on the safe and appropriate use of these medications.
At the same time, regulatory authorities such as the Central Drugs Standard Control Organization must strengthen oversight by strictly enforcing quality standards, enhancing surveillance, and preventing the entry of counterfeit or low-quality drugs into the market.
5. India’s Global Leadership in Generic Drugs
India’s competitive pricing advantage, driven by low-cost manufacturing and strong API capabilities, will accelerate the global reach of semaglutide-based treatments. The semaglutide patent transition also reinforces India’s dominance in the generics space, enabling large-scale production and supply.
As a result, this shift could significantly improve global accessibility to obesity treatments, making advanced therapies more affordable and widely available beyond developed markets.
Conclusion
The semaglutide patent expiry has unlocked a new era for India’s obesity drug market. What was once a premium therapy is rapidly becoming mainstream, potentially transforming how obesity and diabetes are treated across the country.
For businesses, healthcare providers, and policymakers, this is a moment of opportunity and responsibility to ensure that affordability translates into safe, effective, and equitable healthcare access.
FAQ
1. When did the semaglutide patent expire in India?
The semaglutide patent expired in India in March 2026, allowing generic manufacturers to enter the market.
2. Will semaglutide become cheaper after patent expiry?
Yes, prices are expected to drop significantly due to generic competition.
3. What is semaglutide used for?
Semaglutide is used for type 2 diabetes management and weight loss treatment.